Company

Sierra Oncology, Inc.

Headquarters: Vancouver, BC, Canada

Employees: 109

CEO: Dr. Stephen George Dilly M.B.B.S, Ph.D.

NASDAQ: SRRA

Market Cap

$1.34 Billion

USD as of June 1, 2022

Market Cap History

Sierra Oncology, Inc. market capitalization over time

Evolution of Sierra Oncology, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Sierra Oncology, Inc.

Detailed Description

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Sierra Oncology, Inc. has the following listings and related stock indices.


Stock: NASDAQ: SRRA wb_incandescent

Stock: FSX: P7N1 wb_incandescent

Details

Headquarters:

885 West Georgia Street

Suite 2150

Vancouver, BC V6C 3E8

Canada

Phone: 604 558 6536